Managing IP ranks the leading patent firms around the world
This year $50 billion worth of drugs come off patent. The pharma industry’s response will be to focus on personalised medicine and biologics. Eileen McDermott explains how this will shift IP strategy towards trade secrets, data and patenting processes
Benjamin Bai explains why a US decision that expands the jurisdiction of the ITC in trade secrets cases may be flawed, and contrasts it with the limited approach of the Supreme People’s Court in China
The in-house IP lawyer is often given responsibility for social media policy, even though many of the issues are nothing to do with IP infringement. Carmen Glatt and Kim Scallan give some advice on coping with the role
Jeremy Cubert and Eric Silverman introduce readers to Pharmville, USA, a futuristic community of inventors operating after full implementation of the America Invents Act
As the UK announces the details of its Patent Box, local lawyers from six jurisdictions in Europe explain how their tax incentives work and their relative successes
On January 12 the first round of applications for new gTLDs opened, with last-minute concessions from Icann. But were they enough to placate governments and brand owners? Edward Conlon reports
The UK is looking at voluntary codes of conduct for collecting societies, following a proposal made by the Hargreaves Review. There is also talk of a Digital Exchange, and centralised reform from the EU. Managing IP interviews two people on opposite sides of the debate
Test your knowledge of the week’s IP news with our quick, five-question quiz. Answers next week
Read this year's INTA Daily News - published daily by Managing IP direct from the 134th INTA Annual Meeting in Washington DC
May 2012
Do you want to be famous?
Famous, well-known, notorious, reputed: everyone wants enhanced protection for their trade marks. But should they, and what does it mean if it is? Emma Barraclough explains
Will the new post grant and inter partes review proceedings result in more litigators practising pro hac vice before the USPTO?